Successful Treatment with Dupilumab in a Patient with Severe, Difficult to Treat Atopic Dermatitis: Beware of Symptomatic Adrenal Insufficiency due to Abrupt Discontinuation of Pot... by Lieneke F.M. Ariëns, Jorien van der Schaft, Aline M.E. Stades, Anthonie A. van de Woestijne, Marjolein S. De Bruin-Weller

Connect to this object online.

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment by Lieneke F.M. Ariëns, Kirsten J.M. van Nimwegen, Marjan Shams, Digna T. de Bruin, Jorien van der Schaft, Harmieke van Os-Medendorp, Marjolein De Bruin-Weller

Connect to this object online.

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry by Lieneke F.M. Ariëns, Daphne S. Bakker, Lotte S. Spekhorst, Jorien van der Schaft, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman, Marijke Kamsteeg, Marie L.A. Schuttelaar, Marjolein S. De Bruin-Weller

Connect to this object online.

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index by Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os-Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lu, Elena Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein De Bruin-Weller, Laurent Eckert

Connect to this object online.